Codi QR

Important clinical research progress in lung cancer in 2022

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Clinical studies related to adjuvant immunotherapy and neoadjuvant immunotherapy in perioperative NSCLC have been updated. In terms of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chunxia SU, Caicun ZHOU
Format: Artigo
Idioma:Inglês
Publicat: Editorial Office of China Oncology 2023-03-01
Col·lecció:Zhongguo aizheng zazhi
Matèries:
Accés en línia:http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2023.03.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!